Role of Thyrotropin Receptor Antibodies in the Development of Hyperthyroidism: Follow-Up Studies on Nine Patients with Graves’ Disease

Publisher Website
Google Scholar
Abstract
TSH binding inhibitor immunoglobulin (TBII) and thyroid-stimulating antibody (TSAb) activities were measured serially for 4–32 months in nine patients before and during development of hyperthyroidism due to Graves’ disease. Initially, all were euthyroid, seven had thyroid enlargement, one had proptosis, and seven had high serum titers of antithyroid microsomal antibodies. The occurrence of hyperthyroidism was preceded by detection of both TBII and TSAb in four patients and detection of TSAb alone in four patients. One patient had neither TBII nor TSAb when euthyroid. The mean initial TBII and TSAb activities were 10.2 ± 15.2% (±sd) and 2677 ± 4620%, respectively, when these patients were euthyroid. When they became hyperthyroid, both TBII and TSAb activities increased in all patients. At that time, TBII was detected in all but one (eight of nine subjects; 88.9%), with a mean activity of 58.8 ± 23.4% (±sd), and TSAb was detected in all nine patients, with a mean value of 4508 ± 4429%. These findings not only indicate the crucial role of TSH receptor antibodies in the development of hyperthyroidism due to Graves’ disease, but also suggest that a certain period of subclinical Graves’ disease exists before the onset of overt hyperthyroidism in most patients, in the sense that they have TSH receptor antibodies, especially TSAb, in their serum even though they are euthyroid.